We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
-7.49%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$211M
AUM Growth
-$127M
Cap. Flow
-$101M
Cap. Flow %
-47.95%
Top 10 Hldgs %
84.11%
Holding
64
New
9
Increased
4
Reduced
8
Closed
19

Top Buys

Rank Stock Value
1
TRDA icon
Entrada Therapeutics
TRDA
+$1.86M
2
REPL icon
Replimune Group
REPL
+$1.41M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$1.01M
4
TSVT
2seventy bio
TSVT
+$683K
5
AFMD
Affimed
AFMD
+$353K

Top Sells

Rank Stock Value
1
NFH
New Frontier Health Corporation Ordinary Shares
NFH
+$95.7M
2
NFH.WS
New Frontier Health Corporation Warrants, each whole warrant exercisable for one Ordinary Share at a
NFH.WS
+$4.27M
3
TVTX icon
Travere Therapeutics
TVTX
+$1.5M
4
ASND icon
Ascendis Pharma A/S
ASND
+$977K
5
BLUE
bluebird bio
BLUE
+$783K

Sector Composition

Rank Sector Weight
1 Healthcare 98.98%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
26
Acadia Pharmaceuticals
ACAD
$5.03B
$726K 0.34%
29,984
-5,051
-14% -$122K
ALXO icon
27
ALX Oncology
ALXO
$290M
$709K 0.34%
41,950
– –
TSVT
28
DELISTED
2seventy bio
TSVT
$687K 0.33%
+40,273
New +$683K
DBVT
29
DBV Technologies
DBVT
$847M
$590K 0.28%
37,095
– –
STSA
30
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$543K 0.26%
142,900
– –
ASND icon
31
Ascendis Pharma A/S
ASND
$16.8B
$489K 0.23%
4,168
-8,432
-67% -$977K
BMRN icon
32
BioMarin Pharmaceuticals
BMRN
$12.4B
$471K 0.22%
6,115
-1,345
-18% -$113K
AFMD
33
DELISTED
Affimed
AFMD
$355K 0.17%
+8,117
New +$353K
ARGX icon
34
argenx
ARGX
$54.1B
$350K 0.17%
1,110
-20
-2% -$5.82K
RUBY
35
DELISTED
Rubius Therapeutics, Inc
RUBY
$313K 0.15%
56,768
– –
SRPT icon
36
Sarepta Therapeutics
SRPT
$1.77B
$306K 0.15%
+3,917
New +$300K
RETA
37
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$271K 0.13%
8,265
– –
KYNB
38
Kyntra Bio
KYNB
$29.4M
$177K 0.08%
+590
New +$206K
SYBX
39
DELISTED
Synlogic
SYBX
$165K 0.08%
4,576
– –
KOD icon
40
Kodiak Sciences
KOD
$2.84B
$151K 0.07%
19,622
+6,182
+46% +$241K
ABCL icon
41
AbCellera Biologics
ABCL
$2.12B
$122K 0.06%
12,521
-659
-5% -$6.24K
DAWN
42
DELISTED
Day One Biopharmaceuticals
DAWN
$114K 0.05%
11,445
– –
DYN icon
43
Dyne Therapeutics
DYN
$4.9B
$112K 0.05%
11,629
– –
CERS icon
44
Cerus
CERS
$474M
$78K 0.04%
+14,172
New +$78.5K
TCRR
45
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$53K 0.03%
+19,335
New +$60.8K
AMRN
46
Amarin Corp
AMRN
$303M
– –
-1,396
Closed -$94K
BCRX icon
47
BioCryst Pharmaceuticals
BCRX
$2.4B
– –
-15,545
Closed -$215K
BLUE
48
DELISTED
bluebird bio
BLUE
– –
-3,918
Closed -$783K
CNTA
49
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-22,200
Closed -$250K
KURA icon
50
Kura Oncology
KURA
$850M
– –
-11,650
Closed -$163K
1
2
3

Similar funds

MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
MW
Merited Wealth North Bay Village, Florida $121M AUM

Nan Fung Group Holdings's Q1 2022 Portfolio in Review

As of Q1 2022, Nan Fung Group Holdings held 64 positions worth $211M, down 38% from $338M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Nan Fung Group Holdings withdrew a net $101M in Q1 2022, closing 19 positions and reducing 8 holdings. Its most notable exit was New Frontier Health Corporation Ordinary Shares, an estimated $95.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 70% a quarter earlier, followed by Financials.

Against the trend, Nan Fung Group Holdings opened a new position in Entrada Therapeutics worth $1.63M.

  • Nan Fung Group Holdings's largest Q1 2022 buy was Entrada Therapeutics: 173,582 shares worth $1.63M.
  • Nan Fung Group Holdings added most to Kodiak Sciences in Q1 2022, an estimated $241K increase.
  • Nan Fung Group Holdings's biggest Q1 2022 reduction was Ascendis Pharma A/S, cutting an estimated $977K.
  • Nan Fung Group Holdings fully exited New Frontier Health Corporation Ordinary Shares in Q1 2022, selling an estimated $95.7M.
  • Nan Fung Group Holdings's ten largest holdings make up 84% of its $211M portfolio in Q1 2022.
  • Nan Fung Group Holdings opened 9 new positions and closed 19 in Q1 2022.
  • Nan Fung Group Holdings's portfolio value fell 38% quarter-over-quarter to $211M.

Based on Nan Fung Group Holdings's 13F filing for Q1 2022, filed 13 May 2022.